Thus, future clinical studies should focus on the feasibility of using anti-inflammatory strategies for patients with obesity and MDD, who might possibly benefit from reducing systemic inflammatory biomarkers such as CRP. This evidence concerns the gene CRP and obesity due to melanocortin 4 receptor deficiency.